Genetic Testing in KRAS- and EGFR-Mutant Lung Cancers

February 5, 2021

Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.

Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.

Rohs says that genetic testing is especially critical for patients with the lung adenocarcinoma subtype, which is the most common type of lung cancer. Two-thirds of lung adenocarcinoma have actionable mutations for which there are targeted therapies that can treat the disease.

Knowing that there are targeted therpies available for many lung adenocarcinomas is even more of a reason to perform testing on patients.

KRAS and EFGR are 2 of the most common mutations found in the patients subtype. A lot more is known about EFGR and there are numerus treatment options that are safe to use. On the other hand, KRAS has proven to be more of a challenge. Previously, KRAS mutations were considered “untargetable.” However, according to Rohs, this assumption has been challenged by recent success in early clinical trials.